We performed in vivo experiments based on the dosage previously verified and the dosage used in clinics, and found that low-dose (10 μg/kg/day) Dex administration could exert therapeutic effects on AAA via up-regulating ZFP36. The gene discussed is ZFP36; the disease is triple-A syndrome.